Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
O43747

UPID:
AP1G1_HUMAN

ALTERNATIVE NAMES:
Adaptor protein complex AP-1 subunit gamma-1; Adaptor-related protein complex 1 subunit gamma-1; Clathrin assembly protein complex 1 gamma-1 large chain; Gamma1-adaptin; Golgi adaptor HA1/AP1 adaptin subunit gamma-1

ALTERNATIVE UPACC:
O43747; O75709; O75842; Q9UG09; Q9Y3U4

BACKGROUND:
The protein AP-1 complex subunit gamma-1, also referred to as Gamma1-adaptin, is integral to the adaptor protein complex 1, facilitating protein sorting in the late-Golgi/trans-Golgi network and endosomes. Its association with AFTPH/aftiphilin in the aftiphilin/p200/gamma-synergin complex underscores its role in the membrane trafficking of key proteins such as transferrin, furin, and cathepsin D, which are crucial for cellular function and homeostasis.

THERAPEUTIC SIGNIFICANCE:
Involvement of AP-1 complex subunit gamma-1 in Usmani-Riazuddin syndrome, with both autosomal dominant and recessive variants, underscores its clinical significance. These disorders present with global developmental delay, hypotonia, and behavioral abnormalities. Exploring the therapeutic potential of targeting AP-1 complex subunit gamma-1 offers a promising avenue for addressing these challenging neurodevelopmental conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.